CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)
Mukherjee, S. Lord, S. Harman, R. McIntosh, D. Ooms, A. Parkes, M. Radhakrishna, Ganesh Shaw, P. H. Hawkins, M. A.
Mukherjee, S.
Lord, S.
Harman, R.
McIntosh, D.
Ooms, A.
Parkes, M.
Radhakrishna, Ganesh
Shaw, P. H.
Hawkins, M. A.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Mukherjee S, Lord S, Harman R, McIntosh D, Ooms A, Parkes M, et al. CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT). Annals of Oncology. 2022 Sep;33(7):S1120-S. PubMed PMID: WOS:000866211601512.